静脉血栓栓塞的风险与他类药物:通过网络分析收集的证据
Oğuzhan Birdal1, Mehmet Saygı2, Remziye Doğan2
1Department of Cardiology, Atatürk University Faculty of Medicine, Erzurum, Turkey
Balkan medical journal
|July 31, 2023
概括
这一网络分析发现,他类药物,特别是罗斯瓦斯塔丁,显著降低了静脉血栓塞栓症 (VTE) 的风险. 然而,与他类药物和安慰剂相比,费诺纤维酸与VTE风险增加有关.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 抗凝剂是静脉血栓塞栓症 (VTE) 的标准治疗方法.
- 现有研究显示,关于他类药物降低静脉瘤发病率的有效性,结果是相互矛盾的.
研究的目的:
- 进行一个网络元分析,比较降脂剂,以减少VTE风险.
- 确定最有效的药物,以及减少静脉瘤风险的证据最多的药物.
主要方法:
- 随机对照试验 (RCT) 的网络元分析.
- 包括RCT比较他类药物或纤维酸与安慰剂或其他他类药物.
- 搜索了Medline数据库 (1966-2017年) 和有关VTE和他类药物相关研究的相关系统审查.
主要成果:
- 分析了二十七个RCT (n=137,940).
- 与安慰剂相比,他类药物显示VTE的发病率在统计学上显著降低 (0.79%vs0.99%).
- 罗斯瓦斯塔丁表现出最大的静脉瘤风险降低,而费诺纤维酸则显示风险增加.
结论:
- 与安慰剂,其他他类药物和纤维化物相比,罗斯瓦斯塔丁显著降低了静脉瘤风险.
- 与安慰剂和他类药物相比,费诺纤维酸增加了静脉瘤风险.
- 在研究的降脂药物中,罗斯瓦斯塔丁是减少VTE风险的首选药物.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
699
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
699
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
14
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
14
Venous Thrombosis I: Introduction
12
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
12
Venous Thrombosis IV: Nursing Management
14
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
14
Anticoagulant Drugs: Low-Molecular-Weight Heparins
753
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
753


